Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial.

Name: Kaimen Rigor review — Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial.
Item: Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial.
Rating: 59
Author: Alpha1

Wong GL, Yuen MF, Lin B, Douglas MW, Hu P, Xie Q, Lv F, Tak WY, Leerapun A, Kim DJ, Tangkijvanich P, Lim YS, Dai CY, O'Beirne J, Weltman M, Khemnark S, Piratvisuth T, Manasirisuk W, Chen X, Liu CJ, Heo J, Lee J, Niu J, Kumar R, Kumar R, Zhu C, Cao K, Tian A, Chen X, Zhu Q, Margolis D, Jia J, Hong Z

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 2.5★ (Weak), 0 critical, 3 high issues for “Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial.

Read full text (PMC)

DOI

10.1038/s41591-025-04049-z

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/3138f0e3-8780-4228-a596-271d173f5d64" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/3138f0e3-8780-4228-a596-271d173f5d64/badge" alt="Kaimen Rigor review — 2.5★ (Weak), 0 critical, 3 high issues for “Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

6e271455c87c2c3716a3ba4d001ee6b5c954fcc5ff25c85631c39ffc6cdceccb

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial.

Paper source

Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

2.5 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingStudy design partially met−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No reported statistical tests were found to recompute.
The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 5 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy endpoint is HBsAg loss, which is a surrogate marker for functional cure in chronic hepatitis B. The paper does not demonstrate that HBsAg loss at 24 weeks post-treatment translates into hard clinical outcomes such as reduced mortality, cirrhosis, or hepatocellular carcinoma. Although HBsAg loss is a recognized goal, the manuscript does not cite validated evidence linking this surrogate to long-term clinical benefit in the context of this trial, nor does it show target engagement at the tested dose beyond HBsAg reduction.
“Primary endpoints were HBsAg loss at the end of treatment (EOT) and 24 weeks post-EOT.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect sizes are small absolute percentages (e.g., 21.1%, 33.3% vs 5.6% in part I; 29.0% overall in part II) and are not anchored to a minimal clinically important difference or to long-term clinical outcomes. The manuscript does not provide a threshold for clinical meaningfulness of HBsAg loss rates, and the small sample sizes and Bayesian credible intervals suggest uncertainty.
“At 24 weeks post-EOT, HBsAg loss was observed in 4 out of 19 (21.1%) participants receiving elebsiran 200 mg plus PEG-IFNα, 6 out of 18 (33.3%) participants receiving elebsiran 100 mg plus PEG-IFNα and 1 out of 18 (5.6%) participants receiving PEG-IFNα…”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 03AuthenticityNone found 204DisclosureReporting gaps 05AvailabilityNone found 06Copyedit6 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper is a well-conducted phase 2 trial with a clear scientific premise, appropriate statistical methods, and transparent reporting. The main weaknesses are the lack of justification for the open-label design, absence of a formal power analysis for the single-arm cohort, and a vague data availability statement.

Both reviewers classified the study as interventional, which is adopted. The evaluation covers all eight rigor dimensions; no dimensions were excluded as not applicable. The reviewers agreed on all dimensions except study design (one pass, one warn), where the synthesized judgment is 'warn' based on the preponderance of evidence.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions

3 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

4 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

2 findings · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed
Study-design details incomplete (controls, blinding, power)Assessed

Eight Dimensions6 pass · 2 warn

The introduction cites prior studies on elebsiran and PEG-IFNα, acknowledges the lack of a monotherapy control in a prior study, and hypothesizes that BRII-179 responders may benefit more. Limitations of prior research are addressed by including a PEG-IFNα monotherapy control in part I.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study clearly establishes the scientific premise with prior work and a logical rationale.

Evidence

paraphrase[Introduction, paragraph 3]

“A prior study evaluating elebsiran in combination with PEG-IFNα reported an HBsAg loss rate of approximately 30% at the end of treatment (EOT) in participants with chronic HBV infection. However, this study lacked a PEG-IFNα monotherapy control, limiting direct comparison.”

“It was hypothesized that individuals with chronic HBV infection who were able to overcome HBV-induced immune dysfunction following exposure to BRII-179 may have an increased likelihood of mounting an effective immune response upon subsequent treatment with elebsiran and PEG-IFNα, potentially leading to higher rates of functional cure.”

Introduction ¶4Find in source

PASSReviewer 2· 90% conf

The study clearly establishes the scientific premise with prior work and a logical rationale for the combination therapy and biomarker-based patient selection.

Evidence

“However, this study lacked a PEG-IFNα monotherapy control, limiting direct comparison.”

Introduction ¶3Find in source

Introduction ¶4Find in source

Randomization method (Interactive Response Technology) and stratification are reported. Blinding is absent (open-label) but stated. Power analysis is reported for part I but not for cohort 4. Inclusion/exclusion criteria are detailed. Outlier handling is not explicitly described. Controls are present (PEG-IFNα monotherapy). Independent replication is not reported.

Sub-criteria

controlsADEQUATE

power analysisINADEQUATE

blinding levelsINADEQUATE

outlier handlingNOT REPORTED

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationNOT REPORTED

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

The randomized part is adequately designed, but the single-arm cohort 4 lacks randomization and blinding, and the sample size is small.

Evidence

“using an Interactive Response Technology system. The randomization code was generated through a validated computerized system. Participants were stratified at randomization by their HBsAg level at screening (>100 to ≤500 IU ml −1 , >500 to ≤1,500 IU ml −1 and >1,500 to ≤3,000 IU ml −1 ).”

MethodsFind in source

“partially randomized, open-label, phase 2 trial”

AbstractFind in source

paraphrase[Methods, Statistical methods]

“Up to 75 participants were planned to be randomized in a 1:1:1 ratio across cohorts 1–3. The actual sample size was informed by a Bayesian statistical model. ... Up to 45 participants were to be enrolled in cohort 4, and no formal sample size was calculated.”

PASSReviewer 2· 85% conf

The randomized part uses a valid randomization method with stratification, and the study is registered. However, the open-label design and lack of blinding are not justified, and the sample size is small.

Evidence

“using an Interactive Response Technology system. The randomization code was generated through a validated computerized system.”

MethodsFind in source

“This ongoing, open-label, phase 2 study”

MethodsFind in source

“The actual sample size was informed by a Bayesian statistical model.”

Statistical analysisFind in source

Sex, age, race, BMI, HBsAg, HBeAg, and ALT are reported in Table 1. Both sexes are enrolled, so sex justification is not applicable. Demographics are comprehensive.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and baseline characteristics are well reported for this human trial.

Evidence

paraphrase[Table 1]

“Sex n (%) | Male | 16 (88.9) | 17 (89.5) | 14 (77.8) | 47 (85.5) | 23 (74.2)”

PASSReviewer 2· 90% conf

Demographic and baseline characteristics are well reported, including sex, age, race, and disease-related variables.

Evidence

“Male | 16 (88.9) | 17 (89.5) | 14 (77.8) | 47 (85.5) | 23 (74.2)”

Table 1Find in source

“Baseline HBsAg levels ranged from 2.02 to 3.39 log 10 (IU ml −1 ), with a mean (s.d.) of 2.78 (0.37) log 10 (IU ml −1 ).”

ResultsFind in source

The study was approved by an independent ethics committee or IRB at each site, all participants provided written informed consent, and the study was conducted in accordance with the Declaration of Helsinki and ICH-GCP.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethics approval, informed consent, and regulatory compliance are clearly reported.

Evidence

paraphrase[Methods, Study design]

“The study was approved by an independent ethics committee or institutional review board at each site ... and was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation Good Clinical Practice. All participants provided written informed consent to participate in the study before any study-specific procedures were conducted.”

PASSReviewer 2· 95% conf

The study reports ethics approval from an independent ethics committee or IRB at each site, written informed consent, and compliance with the Declaration of Helsinki and ICH-GCP.

Evidence

“The study was approved by an independent ethics committee or institutional review board at each site”

MethodsFind in source

“All participants provided written informed consent to participate in the study before any study-specific procedures were conducted.”

MethodsFind in source

“and was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation Good Clinical Practice.”

MethodsFind in source

Elebsiran and PEG-IFNα are named with doses and regimens. Assays (Cobas, Roche) are identified with LLOQs. No antibodies, cell lines, or mycoplasma testing are applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational products and assays are adequately identified.

Evidence

“Virology assessments included quantitative measurement of serum HBsAg (Cobas, ELECSYS HBsAg II quant II (Roche); LLOQ: 0.05 IU ml −1 )”

MethodsFind in source

“SAS version 9.4 was used for data analyses in this study.”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational products (elebsiran, PEG-IFNα, BRII-179) are identified with dosing regimens, and the assay kits are named with manufacturers. No cell lines or antibodies are used.

Evidence

“cohort 2 (48 doses of PEG-IFNα 180 μg administered SC QW and 13 doses of elebsiran 200 mg administered SC every 4 weeks (Q4W)”

MethodsFind in source

“quantitative measurement of serum HBsAg (Cobas, ELECSYS HBsAg II quant II (Roche); LLOQ: 0.05 IU ml −1 )”

MethodsFind in source

“SAS version 9.4 was used for data analyses in this study.”

Statistical analysisFind in source

Tests are named (Bayesian hierarchical model, mixed model for repeated measures). Assumptions are handled by design. Exact p-values are not reported; instead, credible intervals are used, which is acceptable. Effect sizes are reported with CIs. Software is identified. Data presentation includes individual data points and error bars. Mathematical plausibility checks were not possible due to continuous data and small N.

Sub-criteria

tests namedADEQUATE

exact p valuesN/A

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Statistical methods are appropriate and well described, with Bayesian estimation and mixed models.

Evidence

“For the primary efficacy endpoints, an estimation approach with no hypothesis testing was used for analysis. A Bayesian hierarchical model was used as the primary analysis to estimate the posterior probability of the response rate for each of cohorts 1–3”

Statistical analysisFind in source

“Point estimate of response, % (95% CrI) | 5.4 (0.1, 18.1) | 26.2 (10.3, 45.4) | 33.3 (17.1, 49.5)”

Table 2Find in source

PASSReviewer 2· 80% conf

The statistical methods are appropriate and well described, using Bayesian estimation and mixed models. The paper reports effect estimates with credible intervals, and no p-values are used for primary endpoints.

Evidence

“For the primary efficacy endpoints, an estimation approach with no hypothesis testing was used for analysis.”

Statistical analysisFind in source

“Point estimate of response, % (95% CrI) | 5.4 (0.1, 18.1) | 26.2 (10.3, 45.4) | 33.3 (17.1, 49.5)”

Table 2Find in source

“For cohorts 1–3, changes from baseline in HBsAg (on a log 10 scale) at all scheduled visits were statistically analyzed using a mixed model for repeated measures.”

Statistical analysisFind in source

The data availability statement says deidentified individual participant data will be shared on request or after trial completion, but no platform or timeframe is specified. No code is shared. Since this is a clinical trial, repository deposit is not applicable for patient data.

Sub-criteria

code sharingNOT REPORTED

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

Data availability is stated but vague, with no repository deposit or accession numbers.

Evidence

“Owing to the ongoing nature of the ENSURE study, the deidentified individual participant data that underlie the results reported in this Article will be shared on request, or after the completion of the trial within the timeframe as required by ClinicalTrial.gov”

Data availabilityFind in source

WARNReviewer 2· 80% conf

A data availability statement is present but vague, stating data will be shared on request after trial completion without a concrete mechanism or timeframe.

Evidence

Data availabilityFind in source

The trial is registered (NCT05970289). CONSORT guidelines are followed. All outcomes are reported. Limitations are discussed. Conclusions are proportional. Funding and COI are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The manuscript is well reported, with trial registration, CONSORT adherence, and limitations discussed.

Evidence

paraphrase[Abstract and Methods]

“ClinicalTrials.gov registration: NCT05970289 ... The study adhered to the Consolidated Standards of Reporting Trials (CONSORT) guidelines.”

“This study has some limitations. Approximately 1.5 years, on average, elapsed between the BRII-179-835-001 study and the ENSURE study, and the impact of this gap in time is unknown.”

DiscussionFind in source

PASSReviewer 2· 90% conf

The study is registered, follows CONSORT guidelines, reports all outcomes, discusses limitations, and provides funding and COI statements.

Evidence

“ClinicalTrials.gov registration: NCT05970289”

AbstractFind in source

“The study adhered to the Consolidated Standards of Reporting Trials (CONSORT) guidelines.”

MethodsFind in source

“This study has some limitations.”

Discussion ¶7Find in source

Registered (1 ID: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 24 references by DOI: 19 verified — 5 no DOI (shown, not verified).

1 data/code link checked; 1 live.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly consistency, typo, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

As a post-publication audit, the published work is methodologically sound but has reporting gaps that an informed reader should weigh: the open-label design is not justified, the single-arm cohort lacks a formal sample size calculation, and the data availability statement is vague. These issues do not invalidate the findings but warrant caution in interpretation and could be addressed via a correction or data-sharing clarification.

1.
HIGHreporting
In the Methods (Study design), add a rationale for the open-label design, explaining why blinding was not feasible or why it was not used.
The absence of blinding is a potential source of bias; justifying it helps readers assess the risk.
2.
HIGHreporting
In the Methods (Statistical methods), provide a formal sample size calculation or power analysis for cohort 4, even if exploratory, specifying the effect size, alpha, and power.
Without a sample size justification, the precision of estimates from the single-arm cohort is unclear.
3.
HIGHdata code
In the Data availability section, specify a concrete data access mechanism (e.g., a named data access committee or platform like Vivli) with conditions and a timeframe for sharing.
The current vague statement ('on request') does not meet journal standards for data availability and limits reproducibility.
4.
MEDIUMreporting
In the Methods (Statistical methods), clarify how outliers and missing data were handled in the analysis.
Outlier and missing data handling are essential for reproducibility and are currently not reported.
5.
MEDIUMreporting
In the Discussion, add a statement acknowledging the potential bias introduced by the open-label design as a limitation.
Acknowledging this limitation strengthens the transparency of the manuscript.
6.
MEDIUMdata code
Add a code availability statement in the Data availability section, even if the SAS code is available on request.
Sharing analysis code enhances reproducibility, even if it is not deposited in a public repository.
7.
MEDIUMreporting
In the Methods (Statistical methods), provide more detail on the Bayesian model priors and any sensitivity analyses performed.
Specifying priors and sensitivity analyses improves the reproducibility of the Bayesian analysis.
8.
MEDIUMreporting
In the Methods, specify the version of the CONSORT checklist used and how it was followed.
Explicitly stating the CONSORT version and adherence details strengthens reporting transparency.
9.
LOWcopyedit
In the Discussion, fix the missing space in 'immunological markersare associated' to 'immunological markers are associated'.
Typographical errors reduce readability and professionalism.
10.
LOWcopyedit
In the Methods (Statistical methods), clarify 'post probability' to 'posterior probability'.
The term 'post probability' is non-standard and may confuse readers.
11.
LOWcopyedit
In Table 1, standardize the range notation from '>500- to ≤1,500' to '>500 to ≤1,500'.
Consistent formatting improves clarity.
12.
LOWcopyedit
In the Data availability section, correct the grammatically incomplete sentence: 'For inquiries, the contact person is Z.H. are provided with this paper.' to 'For inquiries, the contact person is Z.H.'
Grammatical errors detract from the manuscript's quality.

Full text (64,019 chars)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial.

Read full text (PMC)

DOI

10.1038/s41591-025-04049-z

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/3138f0e3-8780-4228-a596-271d173f5d64" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/3138f0e3-8780-4228-a596-271d173f5d64/badge" alt="Kaimen Rigor review — 2.5★ (Weak), 0 critical, 3 high issues for “Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

6e271455c87c2c3716a3ba4d001ee6b5c954fcc5ff25c85631c39ffc6cdceccb

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

2.5 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingStudy design partially met−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No reported statistical tests were found to recompute.
The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 5 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy endpoint is HBsAg loss, which is a surrogate marker for functional cure in chronic hepatitis B. The paper does not demonstrate that HBsAg loss at 24 weeks post-treatment translates into hard clinical outcomes such as reduced mortality, cirrhosis, or hepatocellular carcinoma. Although HBsAg loss is a recognized goal, the manuscript does not cite validated evidence linking this surrogate to long-term clinical benefit in the context of this trial, nor does it show target engagement at the tested dose beyond HBsAg reduction.
“Primary endpoints were HBsAg loss at the end of treatment (EOT) and 24 weeks post-EOT.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect sizes are small absolute percentages (e.g., 21.1%, 33.3% vs 5.6% in part I; 29.0% overall in part II) and are not anchored to a minimal clinically important difference or to long-term clinical outcomes. The manuscript does not provide a threshold for clinical meaningfulness of HBsAg loss rates, and the small sample sizes and Bayesian credible intervals suggest uncertainty.
“At 24 weeks post-EOT, HBsAg loss was observed in 4 out of 19 (21.1%) participants receiving elebsiran 200 mg plus PEG-IFNα, 6 out of 18 (33.3%) participants receiving elebsiran 100 mg plus PEG-IFNα and 1 out of 18 (5.6%) participants receiving PEG-IFNα…”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 03AuthenticityNone found 204DisclosureReporting gaps 05AvailabilityNone found 06Copyedit6 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Overstated conclusions

3 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

4 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

2 findings · worst medium

Data/code availability incompleteAssessed
Study-design details incomplete (controls, blinding, power)Assessed

Eight Dimensions6 pass · 2 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study clearly establishes the scientific premise with prior work and a logical rationale.

Evidence

paraphrase[Introduction, paragraph 3]

Introduction ¶4Find in source

PASSReviewer 2· 90% conf

The study clearly establishes the scientific premise with prior work and a logical rationale for the combination therapy and biomarker-based patient selection.

Evidence

“However, this study lacked a PEG-IFNα monotherapy control, limiting direct comparison.”

Introduction ¶3Find in source

Introduction ¶4Find in source

Sub-criteria

controlsADEQUATE

power analysisINADEQUATE

blinding levelsINADEQUATE

outlier handlingNOT REPORTED

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationNOT REPORTED

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

The randomized part is adequately designed, but the single-arm cohort 4 lacks randomization and blinding, and the sample size is small.

Evidence

MethodsFind in source

“partially randomized, open-label, phase 2 trial”

AbstractFind in source

paraphrase[Methods, Statistical methods]

PASSReviewer 2· 85% conf

Evidence

“using an Interactive Response Technology system. The randomization code was generated through a validated computerized system.”

MethodsFind in source

“This ongoing, open-label, phase 2 study”

MethodsFind in source

“The actual sample size was informed by a Bayesian statistical model.”

Statistical analysisFind in source

Sex, age, race, BMI, HBsAg, HBeAg, and ALT are reported in Table 1. Both sexes are enrolled, so sex justification is not applicable. Demographics are comprehensive.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and baseline characteristics are well reported for this human trial.

Evidence

paraphrase[Table 1]

“Sex n (%) | Male | 16 (88.9) | 17 (89.5) | 14 (77.8) | 47 (85.5) | 23 (74.2)”

PASSReviewer 2· 90% conf

Demographic and baseline characteristics are well reported, including sex, age, race, and disease-related variables.

Evidence

“Male | 16 (88.9) | 17 (89.5) | 14 (77.8) | 47 (85.5) | 23 (74.2)”

Table 1Find in source

“Baseline HBsAg levels ranged from 2.02 to 3.39 log 10 (IU ml −1 ), with a mean (s.d.) of 2.78 (0.37) log 10 (IU ml −1 ).”

ResultsFind in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethics approval, informed consent, and regulatory compliance are clearly reported.

Evidence

paraphrase[Methods, Study design]

PASSReviewer 2· 95% conf

The study reports ethics approval from an independent ethics committee or IRB at each site, written informed consent, and compliance with the Declaration of Helsinki and ICH-GCP.

Evidence

“The study was approved by an independent ethics committee or institutional review board at each site”

MethodsFind in source

“All participants provided written informed consent to participate in the study before any study-specific procedures were conducted.”

MethodsFind in source

“and was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation Good Clinical Practice.”

MethodsFind in source

Elebsiran and PEG-IFNα are named with doses and regimens. Assays (Cobas, Roche) are identified with LLOQs. No antibodies, cell lines, or mycoplasma testing are applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational products and assays are adequately identified.

Evidence

“Virology assessments included quantitative measurement of serum HBsAg (Cobas, ELECSYS HBsAg II quant II (Roche); LLOQ: 0.05 IU ml −1 )”

MethodsFind in source

“SAS version 9.4 was used for data analyses in this study.”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational products (elebsiran, PEG-IFNα, BRII-179) are identified with dosing regimens, and the assay kits are named with manufacturers. No cell lines or antibodies are used.

Evidence

“cohort 2 (48 doses of PEG-IFNα 180 μg administered SC QW and 13 doses of elebsiran 200 mg administered SC every 4 weeks (Q4W)”

MethodsFind in source

“quantitative measurement of serum HBsAg (Cobas, ELECSYS HBsAg II quant II (Roche); LLOQ: 0.05 IU ml −1 )”

MethodsFind in source

“SAS version 9.4 was used for data analyses in this study.”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesN/A

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Statistical methods are appropriate and well described, with Bayesian estimation and mixed models.

Evidence

Statistical analysisFind in source

“Point estimate of response, % (95% CrI) | 5.4 (0.1, 18.1) | 26.2 (10.3, 45.4) | 33.3 (17.1, 49.5)”

Table 2Find in source

PASSReviewer 2· 80% conf

Evidence

“For the primary efficacy endpoints, an estimation approach with no hypothesis testing was used for analysis.”

Statistical analysisFind in source

“Point estimate of response, % (95% CrI) | 5.4 (0.1, 18.1) | 26.2 (10.3, 45.4) | 33.3 (17.1, 49.5)”

Table 2Find in source

“For cohorts 1–3, changes from baseline in HBsAg (on a log 10 scale) at all scheduled visits were statistically analyzed using a mixed model for repeated measures.”

Statistical analysisFind in source

Sub-criteria

code sharingNOT REPORTED

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

Data availability is stated but vague, with no repository deposit or accession numbers.

Evidence

Data availabilityFind in source

WARNReviewer 2· 80% conf

A data availability statement is present but vague, stating data will be shared on request after trial completion without a concrete mechanism or timeframe.

Evidence

Data availabilityFind in source

The trial is registered (NCT05970289). CONSORT guidelines are followed. All outcomes are reported. Limitations are discussed. Conclusions are proportional. Funding and COI are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The manuscript is well reported, with trial registration, CONSORT adherence, and limitations discussed.

Evidence

paraphrase[Abstract and Methods]

“ClinicalTrials.gov registration: NCT05970289 ... The study adhered to the Consolidated Standards of Reporting Trials (CONSORT) guidelines.”

“This study has some limitations. Approximately 1.5 years, on average, elapsed between the BRII-179-835-001 study and the ENSURE study, and the impact of this gap in time is unknown.”

DiscussionFind in source

PASSReviewer 2· 90% conf

The study is registered, follows CONSORT guidelines, reports all outcomes, discusses limitations, and provides funding and COI statements.

Evidence

“ClinicalTrials.gov registration: NCT05970289”

AbstractFind in source

“The study adhered to the Consolidated Standards of Reporting Trials (CONSORT) guidelines.”

MethodsFind in source

“This study has some limitations.”

Discussion ¶7Find in source

Registered (1 ID: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 24 references by DOI: 19 verified — 5 no DOI (shown, not verified).

1 data/code link checked; 1 live.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly consistency, typo, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHreporting
In the Methods (Study design), add a rationale for the open-label design, explaining why blinding was not feasible or why it was not used.
The absence of blinding is a potential source of bias; justifying it helps readers assess the risk.
2.
HIGHreporting
In the Methods (Statistical methods), provide a formal sample size calculation or power analysis for cohort 4, even if exploratory, specifying the effect size, alpha, and power.
Without a sample size justification, the precision of estimates from the single-arm cohort is unclear.
3.
HIGHdata code
In the Data availability section, specify a concrete data access mechanism (e.g., a named data access committee or platform like Vivli) with conditions and a timeframe for sharing.
The current vague statement ('on request') does not meet journal standards for data availability and limits reproducibility.
4.
MEDIUMreporting
In the Methods (Statistical methods), clarify how outliers and missing data were handled in the analysis.
Outlier and missing data handling are essential for reproducibility and are currently not reported.
5.
MEDIUMreporting
In the Discussion, add a statement acknowledging the potential bias introduced by the open-label design as a limitation.
Acknowledging this limitation strengthens the transparency of the manuscript.
6.
MEDIUMdata code
Add a code availability statement in the Data availability section, even if the SAS code is available on request.
Sharing analysis code enhances reproducibility, even if it is not deposited in a public repository.
7.
MEDIUMreporting
In the Methods (Statistical methods), provide more detail on the Bayesian model priors and any sensitivity analyses performed.
Specifying priors and sensitivity analyses improves the reproducibility of the Bayesian analysis.
8.
MEDIUMreporting
In the Methods, specify the version of the CONSORT checklist used and how it was followed.
Explicitly stating the CONSORT version and adherence details strengthens reporting transparency.
9.
LOWcopyedit
In the Discussion, fix the missing space in 'immunological markersare associated' to 'immunological markers are associated'.
Typographical errors reduce readability and professionalism.
10.
LOWcopyedit
In the Methods (Statistical methods), clarify 'post probability' to 'posterior probability'.
The term 'post probability' is non-standard and may confuse readers.
11.
LOWcopyedit
In Table 1, standardize the range notation from '>500- to ≤1,500' to '>500 to ≤1,500'.
Consistent formatting improves clarity.
12.
LOWcopyedit
In the Data availability section, correct the grammatically incomplete sentence: 'For inquiries, the contact person is Z.H. are provided with this paper.' to 'For inquiries, the contact person is Z.H.'
Grammatical errors detract from the manuscript's quality.

Full text (64,019 chars)Analyzed: Aug 15, 2026